These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36706952)

  • 1. Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward.
    Akehurst R; Murphy LA; Solà-Morales O; Cunningham D; Mestre-Ferrandiz J; de Pouvourville G
    Value Health; 2023 Apr; 26(4S):11-19. PubMed ID: 36706952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?
    Capkun G; Corry S; Dowling O; Asad Zadeh Vosta Kolaei F; Takyar S; Furtado C; Jónsson P; Kleinermans D; Lambert L; Schiel A; Facey K
    Int J Technol Assess Health Care; 2022 Nov; 38(1):e79. PubMed ID: 36321447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
    Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
    Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making.
    Solà-Morales O; Sigurðardóttir K; Akehurst R; Murphy LA; Mestre-Ferrandiz J; Cunningham D; de Pouvourville G
    Value Health; 2023 Apr; 26(4S):32-42. PubMed ID: 36870678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward.
    Kc S; Lin LW; Bayani DBS; Zemlyanska Y; Adler A; Ahn J; Chan K; Choiphel D; Genuino-Marfori AJ; Kearney B; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Akmal Shafie A; Sui B; Suwantika A; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Teerawattananon Y; Wee HL
    Int J Health Policy Manag; 2023; 12():6858. PubMed ID: 37579427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.
    Zisis K; Pavi E; Geitona M; Athanasakis K
    J Pharm Pharm Sci; 2024; 27():12302. PubMed ID: 38481726
    [No Abstract]   [Full Text] [Related]  

  • 7. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies.
    Sarri G; Hernandez LG
    J Comp Eff Res; 2024 Sep; 13(9):e240061. PubMed ID: 39132748
    [No Abstract]   [Full Text] [Related]  

  • 10. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
    Sievers H; Joos A; Hiligsmann M
    Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of real-world evidence from different data sources in health technology assessment.
    Graili P; Guertin JR; Chan KKW; Tadrous M
    J Pharm Pharm Sci; 2023; 26():11460. PubMed ID: 37529633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
    Hiramatsu K; Barrett A; Miyata Y;
    Drugs Real World Outcomes; 2021 Dec; 8(4):459-480. PubMed ID: 34148219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union.
    Zou KH; Berger ML
    Bioengineering (Basel); 2024 Aug; 11(8):. PubMed ID: 39199742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers.
    Murphy LA; Akehurst R; Solà-Morales O; Cunningham D; Mestre-Ferrandiz J; Franklin M; de Pouvourville G
    Value Health; 2023 Apr; 26(4S):20-31. PubMed ID: 36706951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea.
    Lee H; Ahn HS; Kwon S; Kang HY; Han E
    Clin Transl Sci; 2024 Apr; 17(4):e13801. PubMed ID: 38629484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Real-World Evidence Workstream in EUreccA 2025: How the Task Was Addressed.
    Murphy LA; Akehurst R; Solà-Morales O; Cunningham D; Mestre-Ferrandiz J; Franklin M; de Pouvourville G
    Value Health; 2023 Apr; 26(4S):43-51. PubMed ID: 36642216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.
    Bakker E; Plueschke K; Jonker CJ; Kurz X; Starokozhko V; Mol PGM
    Clin Pharmacol Ther; 2023 Jan; 113(1):135-151. PubMed ID: 36254408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study.
    de Pouvourville G; Cunningham D; Fricke FU; Lindgren P; Mantovani L; Murphy LA; Solà-Morales O; Mestre-Ferrandiz J; Akehurst R
    Value Health; 2023 Apr; 26(4S):3-10. PubMed ID: 36709042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to Deal with the Inevitable: Generating Real-World Data and Using Real-World Evidence for HTA Purposes - From Theory to Action.
    Oortwijn W; Sampietro-Colom L; Trowman R
    Int J Technol Assess Health Care; 2019; 35(4):346-350. PubMed ID: 31198129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
    Yuan L; Rahman M; Concato J
    Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.